Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
Main finding · eGFR decline (eGFR ≥45 group; 16 002 matched pairs)Result — go to the resultDifference 0.25 mL/min/1.73m2 95% CI 0.06–0.44Authors' conclusion
This retrospective real-world study revealed that patients using DPP-4is had a better renal prognosis than those not using DPP-4is.
Study context
- Population
- Patients aged ≥30 years using antidiabetic drugs, 2014–2021, Asian real-world data; analysed in estimated glomerular filtration rate (eGFR) ≥45 and <45 mL/min/1.73m2 groupspropensity-matched pairs
- Exposure
- DPP-4i users vs non-users
- Outcome
- eGFR decline (eGFR ≥45 group) and end-stage kidney disease (ESKD) development (eGFR <45 group)
Methodological detailspropensity score matched, real-world database (DeSC Healthcare, Inc.)
- Propensity score matched
- Real-world database (DeSC Healthcare, Inc.)
Main finding
As reported in the abstract
eGFR decline (eGFR ≥45 group; 16 002 matched pairs) · 2 years
Difference
0.25 mL/min/1.73m2
95% CI 0.06–0.44
By group
DPP-4i users
−2.31
mL/min/1.73m2
Non-users
−2.56
mL/min/1.73m2
DPP-4i usersvs Non-users
difference 0.25 mL/min/1.73m2 (95% CI 0.06–0.44)
Observational data: associations, not effects.
Further findings
mL/min/1.73m2
| Outcome | DPP-4i users | Non-users | Difference (mL/min/1.73m2) (95% CI) | |
|---|---|---|---|---|
| eGFR decline (primary outcome, eGFR ≥45 group) at 3 yearsSmaller decline with DPP-4i users | −2.75 | −3.41 | 0.66 (0.39–0.93) | |
| −0.500.51Difference, mL/min/1.73m2 (linear scale) |
ESKD development (primary outcome, eGFR <45 group; 2086 matched pairs) · mean 2.2 years of observation
log rank P = .005
Original publication
Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users. Diabetes Obes Metab. Published 31 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →